AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 34105988 — intervention group
Group type: COMPARATOR
Intervention: Sham tDCS
Number of subjects: 30
Study 34170946 — intervention group
Group type: EXPERIMENTAL
Intervention: Norway model (healthcare practitioners contact patients' family with information about kidney donation)
Number of subjects: 32
Study 34170946 — intervention group
Group type: EXPERIMENTAL
Intervention: Home education model
Number of subjects: 32
Study 34170946 — intervention group
Group type: EXPERIMENTAL
Intervention: Transplant candidate advocate model
Number of subjects: 32
Study 35162372 — intervention group
Group type: EXPERIMENTAL
Intervention: Exergaming session (EX)
Number of subjects: 28
Study 35162372 — intervention group
Group type: COMPARATOR
Intervention: Endurance exercise (ET)
Number of subjects: 28
Study 35162372 — intervention group
Group type: COMPARATOR
Intervention: Comparison of EX and ET
Number of subjects: 28
Study 35226082 — intervention group
Group type: EXPERIMENTAL
Intervention: Portal messages encouraging a quit attempt with a link to asynchronous care (Group 2)
Number of subjects: 188
Study 35226082 — intervention group
Group type: EXPERIMENTAL
Intervention: Portal messages encouraging a quit attempt without a link to asynchronous care (Group 1)
Number of subjects: 188
Study 35226082 — intervention group
Group type: EXPERIMENTAL
Intervention: Portal messages from the health system with a link to asynchronous care (Group 4)
Number of subjects: 188
Study 35226082 — intervention group
Group type: EXPERIMENTAL
Intervention: Portal messages from the health system without a link to asynchronous care (Group 3)
Number of subjects: 188
Study 35226082 — intervention group
Group type: EXPERIMENTAL
Intervention: Asynchronous care offered
Number of subjects: 188
Study 35226082 — intervention group
Group type: COMPARATOR
Intervention: In-person care offered
Number of subjects: 188
Study 36163944 — intervention group
Group type: EXPERIMENTAL
Intervention: Pegcetacoplan (n=41) in PEGASUS study
Number of subjects: 115
Study 36163944 — intervention group
Group type: EXPERIMENTAL
Intervention: Pegcetacoplan (n=35) in PRINCE study
Number of subjects: 115
Study 36163944 — intervention group
Group type: COMPARATOR
Intervention: Eculizumab (n=39) in PEGASUS study
Number of subjects: 115
Study 36163944 — intervention group
Group type: COMPARATOR
Intervention: Control treatment (n=18) in PRINCE study
Number of subjects: 115
Study 33682614 — intervention group
Group type: EXPERIMENTAL
Intervention: Quitting drinking
Number of subjects: 163
Study 33682614 — intervention group
Group type: EXPERIMENTAL
Intervention: Reducing drinking to ≤7 drinks/week
Number of subjects: 163
Study 33682614 — intervention group
Group type: COMPARATOR
Intervention: Continuing heavy drinking
Number of subjects: 163
Study 33682614 — intervention group
Group type: EXPERIMENTAL
Intervention: Quitting and reducing drinking
Number of subjects: 163
Study 32898010 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy (NAC)
Number of subjects: 140
Study 32898010 — intervention group
Group type: COMPARATOR
Intervention: Surgery first
Number of subjects: 140
Study 33487260 — intervention group
Group type: EXPERIMENTAL
Intervention: Fasted low‐intensity aerobic exercise (50% VO2max) for 45 min followed by an isocaloric high‐fat meal.
Number of subjects: 21
Study 33487260 — intervention group
Group type: EXPERIMENTAL
Intervention: Fasted low‐intensity aerobic exercise (50% VO2max) for 45 min followed by a calorie deficit high‐fat meal.
Number of subjects: 21
Study 33487260 — intervention group
Group type: COMPARATOR
Intervention: Rest and isocaloric high‐fat meal (60% lipids, 30% carbohydrates and 10% protein).
Number of subjects: 21
Study 32467537 — intervention group
Group type: EXPERIMENTAL
Intervention: Incentive spirometry (IS)
Number of subjects: 95
Study 34738474 — intervention group
Group type: EXPERIMENTAL
Intervention: Music-guided exercise intervention (n = 13), individualized music playlist, twice daily for 5 days.
Number of subjects: 26
Study 34738474 — intervention group
Group type: COMPARATOR
Intervention: Active control group (n = 13), exercise brochure, same exercises at same intervals.
Number of subjects: 26
Study 33743490 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetic-fuzzy logic model for measuring stroke volume
Number of subjects: 92
Study 32568111 — intervention group
Group type: EXPERIMENTAL
Intervention: Recommendations by a movement disorder specialist
Number of subjects: 91
Study 32568111 — intervention group
Group type: COMPARATOR
Intervention: Care as usual
Number of subjects: 91
Study 33341915 — intervention group
Group type: EXPERIMENTAL
Intervention: MLH model using PET/MRI radiomics and machine learning
Number of subjects: 52
Study 33341915 — intervention group
Group type: EXPERIMENTAL
Intervention: MBCR model combining MLH, PSA, and clinical stage values
Number of subjects: 52
Study 33341915 — intervention group
Group type: EXPERIMENTAL
Intervention: MOPR model combining MLH, PSA, and clinical stage values
Number of subjects: 52
Study 33341915 — intervention group
Group type: COMPARATOR
Intervention: Standard routine analysis based on PSA, biopsy Gleason score, and TNM staging
Number of subjects: 52
Study 33341915 — intervention group
Group type: COMPARATOR
Intervention: [68Ga]Ga-PSMA-11 SUVmax analysis
Number of subjects: 52
Study 32770491 — intervention group
Group type: EXPERIMENTAL
Intervention: Aphakic intraoperative aberrometry (IA) measurements
Number of subjects: 2
Study 32770491 — intervention group
Group type: COMPARATOR
Intervention: Aphakic/pseudophakic intraoperative aberrometry (IA) measurements
Number of subjects: 2
Study 32770491 — intervention group
Group type: EXPERIMENTAL
Intervention: Aphakic IA measurements
Number of subjects: 2
Study 32770491 — intervention group
Group type: COMPARATOR
Intervention: Aphakic/pseudophakic IA measurements
Number of subjects: 2
Study 32770491 — intervention group
Group type: EXPERIMENTAL
Intervention: Pseudophakic IA measurements
Number of subjects: 2
Study 36386606 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive smoking cessation program (SCP)
Number of subjects: 0
Study 36386606 — intervention group
Group type: EXPERIMENTAL
Intervention: Abbreviated smoking cessation program (SCP)
Number of subjects: 0
Study 36386606 — intervention group
Group type: COMPARATOR
Intervention: Comparator group (general population of adult smokers)
Number of subjects: 0
Study 33891379 — intervention group
Group type: EXPERIMENTAL
Intervention: Bimekizumab (320 mg every 4 weeks for 56 weeks)
Number of subjects: 478
Study 33891379 — intervention group
Group type: COMPARATOR
Intervention: Adalimumab (40 mg every 2 weeks for 24 weeks, then bimekizumab every 4 weeks to week 56)
Number of subjects: 478
Study 33011968 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual triggering with 10,000 units of hCG plus 0.2 mg of triptorelin
Number of subjects: 160
Study 32739240 — intervention group
Group type: EXPERIMENTAL
Intervention: MICS + CCI
Number of subjects: 49
Study 32739240 — intervention group
Group type: COMPARATOR
Intervention: CCI only
Number of subjects: 49
Study 32739240 — intervention group
Group type: COMPARATOR
Intervention: MICS + CCI and CCI only
Number of subjects: 49
Study 35776835 — intervention group
Group type: EXPERIMENTAL
Intervention: Tapentadol (50 mg)
Number of subjects: 21
Study 35776835 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxycodone (10 mg)
Number of subjects: 21
Study 35776835 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study 34358344 — intervention group
Group type: EXPERIMENTAL
Intervention: FC plus low-dose oxytocin
Number of subjects: 220
Study 34358344 — intervention group
Group type: COMPARATOR
Intervention: FC plus placebo
Number of subjects: 220
Study 33872652 — intervention group
Group type: EXPERIMENTAL
Intervention: Astegolimab 490 mg
Number of subjects: 502
Study 33872652 — intervention group
Group type: EXPERIMENTAL
Intervention: Astegolimab 210 mg
Number of subjects: 502
Study 33872652 — intervention group
Group type: EXPERIMENTAL
Intervention: Astegolimab 70 mg
Number of subjects: 502
Study 33872652 — intervention group
Group type: EXPERIMENTAL
Intervention: Astegolimab 490 mg (eosinophil-low)
Number of subjects: 502
Study 33872652 — intervention group
Group type: EXPERIMENTAL
Intervention: Astegolimab 210 mg (eosinophil-low)
Number of subjects: 502
Study 33872652 — intervention group
Group type: EXPERIMENTAL
Intervention: Astegolimab 70 mg (eosinophil-low)
Number of subjects: 502
Study 33872652 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 502
Study 32481325 — intervention group
Group type: EXPERIMENTAL
Intervention: CTO-PCI group (PCI of the non-CTO artery concurrently with the CTO artery)
Number of subjects: 0
Study 32481325 — intervention group
Group type: COMPARATOR
Intervention: non-CTO PCI group (PCI of only the non-CTO artery)
Number of subjects: 0
Study 32481325 — intervention group
Group type: EXPERIMENTAL
Intervention: CTO-PCI group
Number of subjects: 0
Study 35363301 — intervention group
Group type: EXPERIMENTAL
Intervention: Samotolisib (LY3023414) 200 mg twice daily plus enzalutamide 160 mg daily
Number of subjects: 142
Study 35363301 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus enzalutamide 160 mg daily
Number of subjects: 142
Study 35363301 — intervention group
Group type: EXPERIMENTAL
Intervention: Samotolisib (LY3023414) plus enzalutamide
Number of subjects: 142
Study 35363301 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus enzalutamide
Number of subjects: 142
Study 32827413 — intervention group
Group type: EXPERIMENTAL
Intervention: Aromatherapy massage
Number of subjects: 75
Study 32827413 — intervention group
Group type: EXPERIMENTAL
Intervention: Olive-oil massage
Number of subjects: 75
Study 32827413 — intervention group
Group type: COMPARATOR
Intervention: Control (standard care)
Number of subjects: 75
Study 34847073 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional resistance training
Number of subjects: 44
Study 34847073 — intervention group
Group type: EXPERIMENTAL
Intervention: Circular resistance training
Number of subjects: 44
Study 34847073 — intervention group
Group type: EXPERIMENTAL
Intervention: Interval resistance training
Number of subjects: 44
Study 34847073 — intervention group
Group type: COMPARATOR
Intervention: Control group (no exercise)
Number of subjects: 44
Study 33495601 — intervention group
Group type: EXPERIMENTAL
Intervention: Anastrozole
Number of subjects: 528
Study 33495601 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 528
Study 33149022 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous tibial nerve stimulation plus medical treatment (arm A)
Number of subjects: 12
Study 33149022 — intervention group
Group type: COMPARATOR
Intervention: Medical treatment (arm B)
Number of subjects: 12
Study 36153028 — intervention group
Group type: EXPERIMENTAL
Intervention: Early Adolescent Skills for Emotions (EASE) intervention, delivered in 7-weekly adolescent sessions and 3-biweekly caregiver sessions.
Number of subjects: 564
Study 36153028 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control arm (no intervention during the study period).
Number of subjects: 564
Study 33047257 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorthalidone/amiloride (12.5/2.5 mg)
Number of subjects: 97
Study 33047257 — intervention group
Group type: COMPARATOR
Intervention: Losartan (50 mg)
Number of subjects: 97
Study 32023372 — intervention group
Group type: EXPERIMENTAL
Intervention: 4400 IU of vitamin D3 per day during pregnancy
Number of subjects: 0
Study 32023372 — intervention group
Group type: COMPARATOR
Intervention: 400 IU of vitamin D3 per day during pregnancy (control group)
Number of subjects: 0
Study 32023372 — intervention group
Group type: EXPERIMENTAL
Intervention: Prenatal vitamin D supplementation
Number of subjects: 0
Study 33170049 — intervention group
Group type: EXPERIMENTAL
Intervention: Game-Based Training (GBT)
Number of subjects: 49
Study 33170049 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-Based Neuromuscular Training (CBNT)
Number of subjects: 49
Study 33170049 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 49
Study 32277824 — intervention group
Group type: EXPERIMENTAL
Intervention: upadacitinib 7.5 mg
Number of subjects: 197
Study 32277824 — intervention group
Group type: EXPERIMENTAL
Intervention: upadacitinib 15 mg
Number of subjects: 197
Study 32277824 — intervention group
Group type: EXPERIMENTAL
Intervention: upadacitinib 30 mg
Number of subjects: 197
Study 32277824 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 197
Study 32277824 — intervention group
Group type: EXPERIMENTAL
Intervention: upadacitinib
Number of subjects: 197
Study 33625673 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxamate-based HDAC inhibitors using receptor-dependent 4D-QSAR model
Number of subjects: 0
Study 33977947 — intervention group
Group type: EXPERIMENTAL
Intervention: 2S‐hesperidin (500 mg d‐1)
Number of subjects: 40
Study 33977947 — intervention group
Group type: COMPARATOR
Intervention: Placebo (500 mg d‐1 microcellulose)
Number of subjects: 40
Study 35236646 — intervention group
Group type: EXPERIMENTAL
Intervention: Butylphthalide treatment
Number of subjects: 120
Study 35236646 — intervention group
Group type: COMPARATOR
Intervention: Control group (conventional methods)
Number of subjects: 120
Study 33289028 — intervention group
Group type: EXPERIMENTAL
Intervention: Core Elements of Outpatient Antibiotic Stewardship implementation
Number of subjects: 16712
Study 33289028 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 16712
Study 32621263 — intervention group
Group type: EXPERIMENTAL
Intervention: Life Review Therapy and Memory Specificity Training (LRT‐MST)
Number of subjects: 64
Study 33082178 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored letter incorporating patient's screening test results and treatment algorithms sent to family physician
Number of subjects: 148
Study 33082178 — intervention group
Group type: COMPARATOR
Intervention: Generic letter without screening test results sent to family physician (Control)
Number of subjects: 148
Study 35665782 — intervention group
Group type: EXPERIMENTAL
Intervention: Trastuzumab deruxtecan
Number of subjects: 557
Study 35665782 — intervention group
Group type: COMPARATOR
Intervention: Physician's choice of chemotherapy
Number of subjects: 557
Study 34711220 — intervention group
Group type: EXPERIMENTAL
Intervention: Robotic Simulator (RS)
Number of subjects: 40
Study 34711220 — intervention group
Group type: COMPARATOR
Intervention: Laparoscopic Simulator (LS)
Number of subjects: 40
Study 34711220 — intervention group
Group type: EXPERIMENTAL
Intervention: Robotic Simulator (RS) and Laparoscopic Simulator (LS)
Number of subjects: 40
Study 32616329 — intervention group
Group type: EXPERIMENTAL
Intervention: DAPT with clopidogrel and aspirin
Number of subjects: 22
Study 32616329 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum levels of interleukin-18
Number of subjects: 22
Study 34383540 — intervention group
Group type: EXPERIMENTAL
Intervention: Metacognitive interpersonal therapy-group (MIT-G)
Number of subjects: 40
Study 34383540 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (TAU) + waiting list
Number of subjects: 40
Study 34270767 — intervention group
Group type: EXPERIMENTAL
Intervention: Tiered SB parenting model (Video Interaction Project and Family Check-Up)
Number of subjects: 403
Study 35249173 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiofrequency beauty device
Number of subjects: 33
Study 35249173 — intervention group
Group type: COMPARATOR
Intervention: Anti-aging cosmetic
Number of subjects: 33
Study 32171642 — intervention group
Group type: EXPERIMENTAL
Intervention: Specialised diabetes care (SDC)
Number of subjects: 287
Study 32171642 — intervention group
Group type: COMPARATOR
Intervention: Primary care (PC)
Number of subjects: 287
Study 33782719 — intervention group
Group type: EXPERIMENTAL
Intervention: Participants with essential tremor
Number of subjects: 36
Study 33782719 — intervention group
Group type: EXPERIMENTAL
Intervention: Gray matter morphological matrices
Number of subjects: 36
Study 33782719 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 36
Study 32990231 — intervention group
Group type: EXPERIMENTAL
Intervention: Straumann implant
Number of subjects: 86
Study 35571447 — intervention group
Group type: EXPERIMENTAL
Intervention: Transbronchial cryo-biopsy (TBCB)
Number of subjects: 152
Study 35571447 — intervention group
Group type: COMPARATOR
Intervention: Transbronchial lung biopsy (TBLB)
Number of subjects: 152
Study 34036705 — intervention group
Group type: EXPERIMENTAL
Intervention: Computerised cognitive training program (experimental group)
Number of subjects: 30
Study 34036705 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 30
Study 32959223 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceratonia siliqua (carob) syrup twice a day for 3 months
Number of subjects: 60
Study 32959223 — intervention group
Group type: COMPARATOR
Intervention: Vitamin E 100 mg twice a day for 3 months
Number of subjects: 60
Study 32943404 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylprednisolone pulse (intravenous injection, 250 mg·day‐1 for 3 days)
Number of subjects: 68
Study 32943404 — intervention group
Group type: COMPARATOR
Intervention: Standard care alone
Number of subjects: 68
Study 36181769 — intervention group
Group type: EXPERIMENTAL
Intervention: Sacubitril/valsartan
Number of subjects: 4796
Study 36181769 — intervention group
Group type: COMPARATOR
Intervention: Valsartan
Number of subjects: 4796
Study 33542729 — intervention group
Group type: EXPERIMENTAL
Intervention: HF‐rTMS (10.0 Hz over ipsilesional primary motor cortex for 10 consecutive days)
Number of subjects: 33
Study 33542729 — intervention group
Group type: EXPERIMENTAL
Intervention: LF‐rTMS (1.0 Hz over contralesional primary motor cortex for 10 consecutive days)
Number of subjects: 33
Study 33542729 — intervention group
Group type: COMPARATOR
Intervention: Sham group
Number of subjects: 33
Study 32270483 — intervention group
Group type: EXPERIMENTAL
Intervention: High-target mean arterial pressure (70-80 mm Hg)
Number of subjects: 197
Study 32270483 — intervention group
Group type: COMPARATOR
Intervention: Low-target mean arterial pressure (40-50 mm Hg)
Number of subjects: 197
Study 36311634 — intervention group
Group type: COMPARATOR
Intervention: High-frequency group (HFG, 50 Hz)
Number of subjects: 38
Study 36311634 — intervention group
Group type: COMPARATOR
Intervention: Medium-frequency group (MFG, 25 Hz)
Number of subjects: 38
Study 36311634 — intervention group
Group type: EXPERIMENTAL
Intervention: Control group (CG, 0 Hz)
Number of subjects: 38
Study 34476047 — intervention group
Group type: EXPERIMENTAL
Intervention: Debonding plier (DP)
Number of subjects: 80
Study 34476047 — intervention group
Group type: EXPERIMENTAL
Intervention: Ligature cutter (LC)
Number of subjects: 80
Study 34476047 — intervention group
Group type: EXPERIMENTAL
Intervention: Thermal method (TM)
Number of subjects: 80
Study 34476047 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasonic scaler (US)
Number of subjects: 80
Study 34530477 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoperative technology (IT) including computer-assisted navigation (CAN) and robot-assisted surgery (RA)
Number of subjects: 327
Study 34530477 — intervention group
Group type: COMPARATOR
Intervention: Conventional TKA (control group)
Number of subjects: 327
Study 33473021 — intervention group
Group type: EXPERIMENTAL
Intervention: Parenteral iron dextran
Number of subjects: 140
Study 33473021 — intervention group
Group type: COMPARATOR
Intervention: Control (no iron replacement)
Number of subjects: 140
Study 32360827 — intervention group
Group type: EXPERIMENTAL
Intervention: US‐Ax (axillary vein puncture guided by ultrasound)
Number of subjects: 88
Study 32360827 — intervention group
Group type: COMPARATOR
Intervention: CV (cephalic vein dissection)
Number of subjects: 88
Study 32360827 — intervention group
Group type: EXPERIMENTAL
Intervention: US‐Ax
Number of subjects: 88
Study 32360827 — intervention group
Group type: COMPARATOR
Intervention: CV
Number of subjects: 88
Study 33104939 — intervention group
Group type: EXPERIMENTAL
Intervention: Smartwatch
Number of subjects: 73
Study 33104939 — intervention group
Group type: EXPERIMENTAL
Intervention: Smart bracelet
Number of subjects: 73
Study 33104939 — intervention group
Group type: COMPARATOR
Intervention: Mobile app
Number of subjects: 73
Study 36347619 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight-based protocol (Group C, full body)
Number of subjects: 1817
Study 36347619 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight-based protocol (Group D, half body)
Number of subjects: 1817
Study 36347619 — intervention group
Group type: COMPARATOR
Intervention: Conventional protocol (Group A, full body)
Number of subjects: 1817
Study 36347619 — intervention group
Group type: COMPARATOR
Intervention: Conventional protocol (Group B, half body)
Number of subjects: 1817
Study 614284972 — intervention group
Group type: EXPERIMENTAL
Intervention: Smartphone application-delivered notched music therapy and Ginkgo biloba for 3 months
Number of subjects: 26
Study 614284972 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial THI score
Number of subjects: 26
Study 35102532 — intervention group
Group type: EXPERIMENTAL
Intervention: Amiodarone
Number of subjects: 1000
Study 35102532 — intervention group
Group type: EXPERIMENTAL
Intervention: Implantable Cardioverter-Defibrillator (ICD)
Number of subjects: 1000
Study 35102532 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1000
Study 32956506 — intervention group
Group type: EXPERIMENTAL
Intervention: Protocol A (20 ml 2% lidocaine + 10 ml 8.4% sodium bicarbonate)
Number of subjects: 116
Study 32956506 — intervention group
Group type: COMPARATOR
Intervention: Protocol B (20 ml 2% lidocaine + 10 ml 0.9% saline solution)
Number of subjects: 116
Study 32956506 — intervention group
Group type: EXPERIMENTAL
Intervention: Both Protocols
Number of subjects: 116
Study 35191838 — intervention group
Group type: EXPERIMENTAL
Intervention: FFR-guided percutaneous coronary intervention (PCI)
Number of subjects: 0
Study 35191838 — intervention group
Group type: COMPARATOR
Intervention: Angiography-guided percutaneous coronary intervention (PCI)
Number of subjects: 0
Study 32829410 — intervention group
Group type: EXPERIMENTAL
Intervention: Switch to integrase strand transfer inhibitors (INSTIs) including elvitegravir or raltegravir
Number of subjects: 523
Study 32829410 — intervention group
Group type: COMPARATOR
Intervention: Efavirenz with tenofovir disoproxil fumarate
Number of subjects: 523
Study 32829410 — intervention group
Group type: COMPARATOR
Intervention: Efavirenz with abacavir
Number of subjects: 523
Study 36089595 — intervention group
Group type: EXPERIMENTAL
Intervention: diacerein (50mg twice daily)
Number of subjects: 260
Study 36089595 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 260
Study 32912615 — intervention group
Group type: EXPERIMENTAL
Intervention: Anastrozole
Number of subjects: 0
Study 32912615 — intervention group
Group type: EXPERIMENTAL
Intervention: Letrozole
Number of subjects: 0